LARRY NORTON, MD
Osteopathic Medicine at York Ave, New York, NY

2004022, Nov 18, 2004

Dec 12, 2003

10/735180

Larry Norton - New York NY, US

A61K031/704, A61K031/66, A61K031/337

514/034000, 514/109000, 514/449000

Breast cancer is treated by (a) administering to a patient in a first plurality of chemotherapy cycles a therapeutically-effective and well-tolerated amount of doxorubicin in a dose-dense protocol; (b) subsequently administering to the patient in a second plurality of chemotherapy cycles a therapeutically-effective and well-tolerated amount of a taxane chemotherapy agent, for example paclitaxel, in a dose-dense protocol; and (c) subsequently administering to the patient in a third plurality of chemotherapy cycles a therapeutically-effective and well-tolerated amount of cyclophosphainide in a dose-dense protocol. Preferably, the dose dense interval between treatments is about 14 days. The number of cycles in each plurality of chemotherapy cycles is suitably 3 or more, preferably 4. Suitable well-tolerated treatment levels are 60 mg/mof doxorubicin, 175 mg/of paclitaxel, and 600 mg/of cyclophoshamide. A therapeutically effective amount of G-CSF may also be administered during the intervals between treatments in one or more of the chemotherapy cycles.

8175808, May 8, 2012

Mar 20, 2006

11/384882

Larry Norton - New York NY, US

Sloan Kettering Institute for Cancer Research - New York NY

G06F 19/10, G01N 33/48

702 19, 436 64

Techniques for determining optimal duration for treatment of disease include receiving an untreated series of measurements and a treated series of measurements. The untreated series indicates temporal progression of a physical property related to a disease while the disease is untreated. The treated series of measurements indicates temporal progression of the physical property of the disease while a particular treatment is administered. A series of effectiveness values is determined based on the untreated and treated series. Each effectiveness value indicates a ratio between an untreated and a treated rate of change of the physical property at a corresponding time. An elapsed time is determined from start of treatment to an earliest time when an effectiveness value reaches an extreme compared to adjacent effectiveness values. Duration for treatment is based on the elapsed time, and is especially useful for each cycle of dose dense regimes for treatments with toxic side effects.

2007020, Sep 6, 2007

Dec 14, 2006

11/639674

Michael Wigler - Cold Spring Harbor NY, US
James Hicks - Cold Spring Harbor NY, US
Larry Norton - New York NY, US
Anders Zettenberg - Djursholm, SE

C12Q 1/68, G06F 19/00, C07H 21/04

435006000, 702020000, 536024300

The present invention relates to methods and compositions for detecting genomic rearrangements (e.g., amplification) at one or more genetic loci and various applications of such methods and compositions. Examples of genetic loci include HER2, TOP2A and other loci on the human chromosome 17.

7829066, Nov 9, 2010

Dec 27, 2007

12/005302

Joan Massague - New York NY, US
Larry Norton - New York NY, US

Memorial Sloan-Kettering Cancer Center - New York NY

A61K 49/00, C12Q 1/66, C12Q 1/68

424 96, 435 4, 435 6, 435 8

This invention relates, e. g. , to a method for identifying an agent that inhibits a metastatic cell (e. g. that inhibits cancer metastasis), comprising measuring the amount of seeding of a tumor by a detectably labeled, metastatic cell, in a subject, in the presence and absence of a putative agent, wherein the amount of seeding by the metastatic cell is proportional to the metastatic potential of the cell, and wherein a significant amount of inhibition of the seeding by the putative agent indicates that the putative agent is effective to inhibit the metastatic cell (e, g, cancer metastasis). Also described are kits suitable for performing methods of the invention.

2006022, Oct 5, 2006

Mar 24, 2006

11/388881

Ute Dugan - New York NY, US
Larry Norton - New York NY, US

A61K 31/7072

514049000

There is provided a new dosage regimen for capecitabine which maximizes anti-tumor activity while maintaining acceptable toxicity levels.